Isomorphic Labs 与 Merck 合作设计新型癌症药物
Hassabis 的 Isomorphic Labs 拿下了 Merck 的合作,要用 AI 直接设计一款癌症药。AlphaFold 团队下场做药,和 Recursion、Insilico 这些同行比路径更偏结构生物学,做药企研发的人可以关注细节。
Demis Hassabis 宣布 Isomorphic Labs 与 Merck(MSD)达成战略合作,共同设计一款新的癌症药物。
合作将 Isomorphic Labs 的前沿 AI 能力与 MSD 在药物发现、开发和制造方面的深厚经验结合。Isomorphic Labs 是 Hassabis 在 AlphaFold 之后创立的 AI 药物发现公司,此次合作被视为其 AI 设计药物路线的又一个实际验证案例。
对制药行业来说,大型药企与 AI 原生实验室的绑定正在成为新药管线的常见组织方式,这单合作的具体靶点和分成结构尚未披露。
Fantastic to be collaborating with Merck on designing a new cancer drug - another important proof point of the rapid progress we’re making at Iso on reimagining drug discovery! Isomorphic Labs @IsomorphicLabs Today, we enter a strategic research collaboration with @MSDInvents . The collaboration brings together Isomorphic Labs’ world-leading frontier AI capabilities with MSD’s deep discovery, development and manufacturing expertise. Read more: isomorphiclabs.com/articles/isomo… 🔗 View Quoted Tweet📊 77 ⚡
This report is categorized under AITOP's "Industry" desk, focusing on Europe's AI governance and technology ecosystem. Within our cross-regional analytical framework, it directly maps to AI developer toolchains, coding agents, and engineering workflows. Key entities and technical topics under continuous tracking include Isomorphic Labs, Merck, drug discovery, AlphaFold.
Source attribution: curated from Demis Hassabis (@demishassabis).